There are plenty of companies making inroads in the field of cancer research, and one of the more interesting companies of the past decade or so has been Seattle Genetics. I had a chance to recently see CEO Clay Siegall speak at an event and came away impressed with some of the innovations the company's focused on as they continue to make advancements in cancer therapy. The fact that their stock price has roughly tripled over the span of 5 years showcases the company's growing role in the field.
As CEO of Seattle Genetics, Dr. Siegall has been passionate about improving the lives of cancer patients since he started his career in biomedical studies. He currently serves as the president, CEO, and chairman of the board of Seattle Genetics. Dr. Siegall has served as the chief executive officer since 2002. He has almost two decades of history with this innovative company since he co-founded it in 1998. Since then, Dr. Siegall has worked tirelessly to lead the company to great advancements in cancer research and ground-breaking therapies for cancer patients.
Since earning his Ph.D. in Genetics from George Washington University, Dr. Siegall has amassed quite a list of professional accomplishments. He began his career in research as a Senior Research Investigator at the Bristol-Myers Squibb Pharmaceutical Research Institute. Dr. Siegall was promoted to the position of Principal Scientist before moving on to become a Staff Fellow and Biotechnology Fellow at the National Cancer Institute. After this advancement, Siegall began to help launch Seattle Genetics.
At the core of all of Siegall's professional achievements has been a commitment to concentrating on important research and being diligent about implementing the most cutting-edge research developments. He has been consistently guided by a true desire to help patients and is incredibly motivated to help alleviate their suffering. This passion and drive have help Siegall take the company to entirely new levels in terms of research advancements. For example, under Dr. Siegall's leadership, Seattle Genetics developed the first antibody-drug conjugates (ADCs), including ADCETRIS® (brentuximab vedotin), which secured FDA approval in 2011. ADCETRIS® is expanding its global impact and is now available to help cancer patients in more than 60 countries around the world. Dr. Siegall's influence in the development and promotion of this ADC is a testament to his perseverance and steadfast dedication to making sure that the medical community continues to prioritize cancer therapies for years to come. He was an integral part of ensuring that ADCETRIS® gained FDA approval and is made available to as many patients around the world as can benefit from it.
In addition to being known as a leader in the field of new cancer therapies, Dr. Siegall has demonstrated exemplary leadership abilities in his role in helping to fundraise more than $1.2 billion in public and private funding for Seattle Genetics. This massive infusion of capital has allowed Seattle Genetics to continue to pave the way in advancements in cancer treatments with the most innovative technology. Dr. Siegall represents a very rare combination of scientific acumen as well as visionary leadership to help propel scientific advancement to new heights.
In recognition of Dr. Siegall's significant contributions to the scientific and medical communities, he received the University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences in 2013. In 2012, he was also named the Pacific Northwest Ernst & Young Entrepreneur of the Year.
Siegall shows no signs of slowing down with his enthusiasm for leading the pack in new scientific achievements. He currently holds 15 patents and is constantly searching for ways to reach new heights in medical research. His contributions to the scientific community include publishing extensively on new research methods and discoveries. Right now, Siegall has published more than 70 scientific articles and continues to share his in-depth knowledge with the scientific and medical communities. In addition, he holds prominent positions on the editorial boards of three scientific journals and is committed to providing research and publishing opportunities for other scientists who share his passion for moving medicine forward so that cancer patients no longer have to suffer.
Keep an eye on this company as